Mohammad A. El-Kalay
Plus aucun poste en cours
Profil
Mohammad A.
El-Kalay was the founder who founded EyeCyte, Inc. in 2008 and served as President & Chief Executive Officer in 2010.
He also held former positions as Director-Product Development at Applied Immune Sciences, Inc., Systemix, Inc., and Osiris Corp.
He was Vice President-Process Development at StemCells, Inc., Vice President-Technical Operations at Sangamo Therapeutics, Inc., Vice President-Product Development at Morphogenesis, Inc., Vice President-Research & Development at MicroIslet, Inc., and Senior Vice President-Research & Development at Telos Pharmaceuticals LLC.
Dr. El-Kalay received his undergraduate, graduate, and doctorate degrees from the University of Strathclyde.
Anciens postes connus de Mohammad A. El-Kalay
| Sociétés | Poste | Fin |
|---|---|---|
StemCells, Inc.
 StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Corporate Officer/Principal | - |
| SANGAMO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Systemix, Inc.
 Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Corporate Officer/Principal | - |
Applied Immune Sciences, Inc.
 Applied Immune Sciences, Inc. Medical SpecialtiesHealth Technology Part of Sanofi, Applied Immune Sciences, Inc. is a surgical and medical instruments company. The private company is based in Menlo Park, CA. The company was founded by Thomas B. Okarma. Applied Immune Sciences was acquired by Rhone-Poulenc Rorer, Inc. on November 28, 1995 for $84.40 million. | Corporate Officer/Principal | - |
| OSIRIS CORPORATION | Corporate Officer/Principal | - |
Formation de Mohammad A. El-Kalay
| University of Strathclyde | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| OSIRIS CORPORATION | Producer Manufacturing |
| Entreprise privées | 7 |
|---|---|
Applied Immune Sciences, Inc.
Applied Immune Sciences, Inc. Medical SpecialtiesHealth Technology Part of Sanofi, Applied Immune Sciences, Inc. is a surgical and medical instruments company. The private company is based in Menlo Park, CA. The company was founded by Thomas B. Okarma. Applied Immune Sciences was acquired by Rhone-Poulenc Rorer, Inc. on November 28, 1995 for $84.40 million. | Health Technology |
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Health Technology |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Health Services |
Morphogenesis, Inc.
 Morphogenesis, Inc. BiotechnologyHealth Technology Morphogenesis, Inc. develops targeted immunotherapies research. It focuses on the development of cell and gene therapies for the treatment of cancer. The company was founded by Patricia Lawman and Michael Lawman in 1990 and is headquartered in Tampa, FL. | Health Technology |
MicroIslet, Inc.
 MicroIslet, Inc. Miscellaneous Commercial ServicesCommercial Services MicroIslet, Inc. operates as a biotechnology company, which researches, develops, and commercializes patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. The company was founded on August 21, 1998 and is headquartered in San Diego, CA. | Commercial Services |
EyeCyte, Inc.
 EyeCyte, Inc. Pharmaceuticals: MajorHealth Technology EyeCyte, Inc. develops products for the treatment of retinal disease. It focuses on treatments for age-related macular degeneration (AMD) and diabetic retinopathy. The company was founded by Mohammad El-Kalay and Martin Friedlander in 2008 and is headquartered in La Jolla, CA. | Health Technology |
| Telos Pharmaceuticals LLC |
